Antihyperlipidemic effect of selected pyrimidine derivatives mediated through multiple pathways.
anti-inflammatory
antihyperlipidemic
antioxidant
computational pharmacology
hepatoprotective
pyrimidines
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
30
03
2021
received:
21
11
2020
accepted:
14
04
2021
pubmed:
20
4
2021
medline:
14
1
2022
entrez:
19
4
2021
Statut:
ppublish
Résumé
Hyperlipidemia is worth-mentioning risk factor in quickly expanding atherosclerosis, myocardial infarction, and stroke. This study attempted to determine effectiveness of selected pyrimidine derivatives: 5-(3-Hydroxybenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-5), 5-(4-Hydroxybenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-8), 5-(3-Chlorobenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-9), and 5-(4-Chlorobenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-10) against hyperlipidemia. In silico results revealed that SR-5, SR-8, SR-9, and SR-10 exhibited high affinity with 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) possessing binding energy values of -8.2, -8.4, -8.6, and -9.5 Kcal/mol, respectively, and moderate (<-8 Kcal/mol) against other selected targets. In vivo findings showed that test drugs (25 and 50 mg/Kg) significantly decreased HFD rat total cholesterol, triglycerides, low-density lipoprotein, very-low-density lipoprotein, atherogenic index, coronary risk index, alkaline phosphatase, aspartate transaminase, alanine transaminase, and bilirubin and increased high-density lipoprotein (p < 0.05, p < 0.01, p < 0.001 vs HFD group). In animal liver tissues, SR-5, SR-8, SR-9, and SR-10 inhibited HMGCoA reductase enzyme, enhanced glutathione-s-transferase, reduced glutathione, catalase levels, improved cellular architecture in histopathological examination, and decreased expression of inflammatory markers: cyclo-oxygenase 2, tumor necrosis factor alpha, phosphorylated c-Jun N-terminal kinase, and phosphorylated-nuclear factor kappa B, evidenced in immunohistochemistry and enzyme-linked immunosorbent assay molecular investigations. This study indicates that SR-5, SR-8, SR-9, and SR-10 exhibit antihyperlipidemic action, mediated possibly through HMGCoA inhibition, hepatoprotection, antioxidant, and anti-inflammatory pathways.
Substances chimiques
Antihypertensive Agents
0
Antioxidants
0
Hypolipidemic Agents
0
Pyrimidines
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1119-1132Informations de copyright
© 2021 Société Française de Pharmacologie et de Thérapeutique.
Références
Yang Z, Wang J, Li J et al. Antihyperlipidemic and hepatoprotective activities of polysaccharide fraction from Cyclocarya paliurus in high-fat emulsion-induced hyperlipidaemic mice. Carbohydr Polym. 2018;183:11-20.
Aladaileh SH, Saghir S, Murugesu K et al. Antihyperlipidemic and antioxidant effects of Averrhoa carambola extract in high fat diet fed rats. Biomedicines. 2019;7:72.
Ma L, Xie C, Ran Y et al. Synthesis and biological evaluation of 5-benzylidenepyrimidine 2, 4, 6(1H, 3H, 5H) -trione derivatives for the treatment of obesity related nonalcoholic fatty liver disease. J Med Chem. 2012;55:9958-9972.
Singh R, Chouhan A. An Overview of biological importance of pyrimidine. World J Pharm Pharm Sci. 2014;3:574-597.
Li JT, Dai HG, Liu D, Li TS. Efficient method for synthesis of the derivatives of 5-arylidene barbituric acid catalyzed by aminosulfonic acid with grinding. Synth Commun. 2006;36:789-794.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4-17.
Duhovny SD, Rossi A, Avila-Sakar A et al. A method for integrative structure determination of protein-protein complexes. Bioinformatics. 2012;28:3282-3289.
Hassan M, Ashraf Z, Abbas Q, Raza H, Seo SY. Exploration of novel human tyrosinase inhibitors by molecular modeling, docking and simulation studies. Interdiscip Sci. 2018;10:68-80.
Aqeel MT, Ur-Rahman N, Khan AU et al. Antihyperlipidemic studies of newly synthesized phenolic derivatives: in silico and in vivo approaches. Drug Des Devel Ther. 2018;12:2443-2453.
Ma L, Li S, Zheng H et al. Synthesis and biological activity of novel barbituric acid and thiobarbituric acid derivatives against non-alcoholic fatty liver disease. Eur J Med Chem. 2011;46:2003-2010.
Zheng H, Li S, Ma L et al. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. Eur J Pharmacol. 2011;659:244-251.
Ma L, Caifeng X, Yan R et al. Synthesis and biological evaluation of 5-benzylidenepyrimidine 2, 4, 6 (1H, 3H, 5H) - trione derivatives for the treatment of obesity related nonalcoholic fatty liver disease. J Med Chem. 2012;55:9958-9972.
El-Deen RM, Heeba GH, Abdel-latif RG, Khalifa MMA. Comparative effectiveness of phosphodiesterase 3, 4 and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. Fundam Clin Pharmacol. 2020;34:353-364.
Wang W, Liu H, Zhang Y. Antihyperlipidemic and hepatoprotective properties of alkali- and enzyme-extractable polysaccharides by Dictyophora indusiata. Sci Rep. 2019;9:14266.
Beyegue CFN, Ngangoum RMC, Ngondi DKJL, Oben JE. Effect of Guibourtia tessmannii extracts on blood lipids and oxidative stress markers in triton WR 1339 and high fat diet induced hyperlipidemic rats. Biol Med. 2012;4:1-9.
Alvi AM, Kury LTA, Ijaz MU et al. Post-treatment of synthetic polyphenolic 1,3,4 oxadiazole compound A3 attenuated ischemic stroke-induced neuroinflammation and neurodegeneration. Biomolecules. 2020;10:816.
Chan KW, Ismail M, Esa NM, Imam MU, Ooi DJ, Khong MH. Dietary supplementation of defatted kenaf (Hiniscus cannabinus L.) seed meal and its phenolics-saponins rich extract effectively attenuates diet-induced hypercholesterolemia in rats. Food Funct. 2018;9:925-936.
Shaker ME, Salem HA, Shiha GE, Ibrahim TM. Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam Clin Pharmacol. 2011;25:248-257.
Gao L, Lin Z, Liu Y et al. Hypolipidemic effect of Fragarianilgerrensis schlecht medicine compound on hyperlipidemic rats. Lipids Health Dis. 2018;17:222.
Xia H, He Q, Wang H et al. Treatment with either COX-2 inhibitor or 5-LOX inhibitor causes no compensation between COX-2 pathway and 5-LOX pathway in chronic aluminum overload-induced liver injury in rats. Fundam Clin Pharmacol. 2019;33:535-543.
Bezerra RMN, Veiga LF, Caetano AC et al. Caffeic acid phenethyl ester reduces the activation of the nuclear factor κB pathway by high-fat diet-induced obesity in mice. Metabolism. 2012;61:1606-1614.
Morris GM, Wilby LM. Molecular docking. molecular modeling of proteins. Humana Press, New York. 2008:365-382.
Pecsi I, Leveles I, Harmat V, Vertessy BG, Toth J. Aromatic stacking between nucleobase and enzyme promotes phosphate ester hydrolysis in dUTPase. Nucleic Acids Res. 2010;38:7179-7186.
Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277-283.
Kastelein JJP, van der Steeg WA, Holme I. Lipids, apolipoproteins and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002-3009.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376:1670-1681.
Min HK, Kapoor A, Fuchs M et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of non-alcoholic fatty liver disease. Cell Metab. 2012;15:665-674.
Kakimoto PA, Kowaltowski AJ. Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biol. 2016;8:216-225.
Guzzaloni G, Grugniv G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obes. 2000;24:772-776.
Lasker S, Rahman MM, Parvez F et al. High-fat diet-induced metabolic syndrome and oxidative stress in obese rats are ameliorated by yogurt supplementation. Sci Rep. 2019;9:20026.
Mohammadi AA, Jazayeri S, Khosravi-Darani K et al. Effects of probiotics on biomarkers of oxidative stress and inflammatory factors in petrochemical workers: a randomized, double-blind, placebo-controlled trial. Int. J Prev Med. 2015;6:82.
Jiang CX, Xiong QP, Gan D, Jiao YP, Liu J, Ma LP. Antioxidant activity and potential hepatoprotective effect of polysaccharides from Cyclina sinensis. Carbohydr Polym. 2013;91:262-268.
Srinath R, Venkataranganna M, Saravanan J. Anti-hyperlipidemic activity of thieno - [2, 3-d] - pyrimidin-4(3H)-ones. Maced J Med Sci. 2011;4:358-366.
Bhat MA, Al-Omar MA, Khan AA, Alanazi AM, Naglah AM. Synthesis and antihepatotoxic activity of dihydropyrimidinone derivatives linked with 1, 4-benzodioxane. Drug Des Devel Ther. 2019;13:2393-2404.
De Souza CT, Araujo EP, Bordin S et al. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology. 2005;146:4192-4199.
Vykhovanets EV, Shankar E, Vykhovanets OV, Shukla S, Gupta S. High-fat diet increases NF-κB signaling in the prostate of reporter mice. Prostate. 2011;71:147-156.
Hommes DW, Peppelenbosch MP, van Deventer SJH. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut. 2003;52:144-151.
Hernandes MZ, Cavalcanti SM, Moreira DR, de Azevedo JWF, Leite AC. Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets. 2010;11:303-314.
Zhijian XU, Yang Z, Yingtao L, Yunxiang LU, Kaixian C, Weiliang Z. Halogen bond: its role beyond drug-target binding affinity for drug discovery and development. J Chem Inform Model. 2014;54:69-78.
Alagarsamy V, Meena S, Rameshu KV. Synthesis, analgesic, anti-inflammatory, ulcerogenic index and antibacterial activities of novel 2-methylthio-3-substituted-5, 6, 7, 8-tetrahydrobenzo (b) thieno [2, 3-d] pyrimidine-4(3H)-ones. Eur J Med Chem. 2006;41:1293-1300.
Zhang Y, Luo LU, Han C. Design, synthesis and biological activity of tetrahydrobenzo [4,5] thieno[2,3-d]pyrimidine derivatives as anti-inflammatory agents. Molecules. 2017;22:1-21.